Exosomal MicroRNA-Based Predictive Model for Preclinical Alzheimer's Disease: A Multicenter Study

Area of Science:

• Neuroscience
• Biomarker Discovery
• Genomics

Background:

• Exosomal microRNAs (miRNAs) are recognized biomarkers for Alzheimer's disease (AD).
• The predictive capacity of exosomal miRNAs for asymptomatic or preclinical AD remains largely uninvestigated.

Purpose of the Study:

• To validate the efficacy of exosomal miRNAs in identifying Alzheimer's disease (AD) during its preclinical stages.
• To assess the potential of exosomal miRNAs as early diagnostic markers for AD.

Main Methods:

• A multicenter study utilizing four independent datasets.
• Inclusion of diverse cohorts: pilot AD vs. control, larger Chinese cohort, longitudinal preclinical AD cohort, and familial AD cohort.
• Analysis of exosomal miRNA panels for diagnostic accuracy.

Main Results:

• A specific panel of exosomal miRNAs demonstrated altered levels in subjects with AD.
• This miRNA panel accurately identified preclinical AD 5 to 7 years before the onset of cognitive impairment.
• High diagnostic accuracy was achieved, with areas under the curve ranging from 0.85 to 0.88.

Conclusions:

• Exosomal miRNAs are effective biomarkers for predicting Alzheimer's disease.
• Early detection of preclinical AD is feasible 5-7 years prior to clinical symptom manifestation.
• This finding supports the development of novel diagnostic tools for early AD intervention.